Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9799605 | 0.89 | RAB9A (0.37) | RAB9A | |
| SCHEMBL7638150 | 0.83 | HMGCR (0.39) | RAB9A | |
| SCHEMBL7064859 | 0.82 | — | — | |
| SCHEMBL4514852 | 0.81 | — | — | |
| SCHEMBL6319883 | 0.79 | PTPN7 (0.47) | — | |
| SCHEMBL28104428 | 0.78 | RAB9A (0.31) | RAB9A | |
| SCHEMBL31336402 | 0.75 | RAB9A (0.48) | RAB9A | |
| SCHEMBL9208114 | 0.74 | RAB9A (0.36) | RAB9A | |
| SCHEMBL7179774 | 0.72 | PTPN7 (0.45) | — | |
| SCHEMBL18338964 | 0.72 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014070774-A1 | METHODS OF GENERATING BETA-LACTAMASE RESISTANT CARBAPENEM COMPOUNDS | SOUTHERN METHODIST UNIVERSITY (US) | 2014-05-08 | — | — | WO | disclosed |
| US-6828338-B2 | Protease inhibitor; anticoagulant | PHARMACIA CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-6770759-B2 | CEPHALOSPORINS FOR TREATING A BETA -LACTAM RESISTANT BACTERIAL INFECTION IN A MAMMAL; ENZYME INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20040002494-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-6624180-B2 | Such as 2-(2-(N-((4-aminoiminomethylphenyl)methyl)-3-(3-aminophenyl)-6-(N,N -dimethylhydrazino)-1-oxypyridinyl))acetami de which inhibit serine proteases for preventing and treating thrombotis | PHARMACIA CORPORATION | 2003-09-23 | — | — | US | disclosed |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002494-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | RAB9A 3104/4885 |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | RAB9A 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.